ProposalWorkspaceFederal OpportunitiesDepartment of Health and Human Services

Takeda Group's Gammagard (Notice of Intent to Sole Source)

Active NOI-27-000636 PresolicitationNational Institutes of Health
The full text, documents and contacts of this bid come with a ProposalWorkspace plan.Get started

At a glance

National Institutes of Health - CC of National Institutes of Health posted this Presolicitation on Nov 13, 2026. Responses are due Nov 16, 2026. NAICS 3254 (Pharmaceutical and Medicine Manufacturing), product or service code 6505 (Drugs and Biologicals). Place of performance: Maryland 20814. Solicitation number NOI-27-000636.

Solicitation details

General information

Solicitation number
NOI-27-000636
Notice type
Presolicitation
Place of performance
Maryland 20814

Classification

NAICS
3254Pharmaceutical and Medicine Manufacturing
Product or service
6505Drugs and Biologicals

Agency

Department
Department of Health and Human Services
Sub-tier
National Institutes of Health
Office
National Institutes of Health - CC

Description

From SAM.gov

Acquisition Description:

This is a Notice of Intent, not a request for proposal.  The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Takeda Pharmaceutical Company Limited.

The National Institutes of Health (NIH) Clinical Center (CC) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. This includes the purchase of Gammagard S/D 10gm and Gammagard S/D 5gm kits.

The NIH CC Pharmacy is requesting the purchase of 10 bottles each of Gammagard S/D 10gm and Gammagard S/D 5gm kits and as needed to provide anticipated current patient care need.

Justification:

TAKEDA Group is the only responsible source for Gammagard S/D. There are multiple patients in the NIH currently on therapy with Gammagard S/D and additional patients may be transferred to the NIH for evaluation and treatment. Gammagard S/D is on the Clinical Center’s formulary, requiring a supply to be available in the Pharmacy Department at all times to support ongoing patient care. The NIH needs to keep using the same items to keep treatment consistent. 

More from National Institutes of Health

Open bids, other NAICS codes